We are comparing Audentes Therapeutics Inc. (NASDAQ:BOLD) and Mesoblast Limited (NASDAQ:MESO) on their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Audentes Therapeutics Inc.	N/A	0.00	117.60M	-2.72	0.00
Mesoblast Limited	27.80M	14.92	47.77M	-0.50	0.00

In table 1 we can see Audentes Therapeutics Inc. and Mesoblast Limited’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows Audentes Therapeutics Inc. and Mesoblast Limited’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Audentes Therapeutics Inc.	0.00%	-40.5%	-37.5%
Mesoblast Limited	-171.83%	-8.7%	-7%

Liquidity

The Current Ratio of Audentes Therapeutics Inc. is 14.8 while its Quick Ratio stands at 14.8. The Current Ratio of rival Mesoblast Limited is 3.6 and its Quick Ratio is has 3.6. Audentes Therapeutics Inc. is better equipped to clear short and long-term obligations than Mesoblast Limited.

Insider & Institutional Ownership

Roughly 91.7% of Audentes Therapeutics Inc. shares are owned by institutional investors while 3% of Mesoblast Limited are owned by institutional investors. Insiders owned 0.9% of Audentes Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Audentes Therapeutics Inc.	-4.62%	-3.76%	-34.73%	-40.11%	-19.28%	-25.38%
Mesoblast Limited	-12.55%	-47.53%	-27.35%	-30.56%	-18.74%	-27.23%

For the past year Audentes Therapeutics Inc.’s stock price has smaller decline than Mesoblast Limited.

Summary

Mesoblast Limited beats Audentes Therapeutics Inc. on 6 of the 9 factors.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.